CoChat

Genetic inactivation of the p66 isoform of ShcA is neuroprotective in a murine model of multiple sclerosis

Open access
Su, Kimmy G., Savino, Costanza, Marracci, Gail, Chaudhary, Priya, Yu, Xiaolin, Morris, Brooke, Galipeau, Danielle, Giorgio, Marco, Forte, Michael, Bourdette, Dennis · 2012 · European Journal of Neuroscience
Cited by 28

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Although multiple sclerosis (MS) has traditionally been considered to be an inflammatory disease, recent evidence has brought neurodegeneration into the spotlight, suggesting that accumulated damage and loss of axons is critical to disease progression and the associated irreversible disability. Proposed mechanisms of axonal degeneration in MS posit cytosolic and subsequent mitochondrial Ca 2+ overload, accumulation of pathologic reactive oxygen species (ROS), and mitochondrial dysfunction leading to cell death. In this context, the role of the p66 isoform of ShcA protein (p66) may be significant. The ShcA isoform is uniquely targeted to the mitochondrial intermembrane space in response to elevated oxidative stress, and serves as a redox enzyme amplifying ROS generation in a positive feedforward loop that eventually mediates cell death by activation of the mitochondrial permeability transition pore. Consequently, we tested the hypothesis that genetic inactivation of p66 would reduce axonal injury in a murine model of MS, experimental autoimmune encephalomyelitis (EAE). As predicted, the p66‐knockout (p66‐KO) mice developed typical signs of EAE, but had less severe clinical impairment and paralysis than wild‐type (WT) mice. Histologic examination of spinal cords and optic nerves showed significant axonal protection in the p66‐KO tissue, despite similar levels of inflammation. Furthermore, cultured p66‐KO neurons treated with agents implicated in MS neurodegenerative pathways showed greater viability than WT neurons. These results confirm the critical role of ROS‐mediated mitochondrial dysfunction in the axonal loss that accompanies EAE, and identify p66 as a new pharmacologic target for MS neuroprotective therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1460-9568.2011.07972.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 28

Metadata

Authors
Su, K. G., Savino, C., Marracci, G., Chaudhary, P., Yu, X., Morris, B., Galipeau, D., Giorgio, M., Forte, M., & Bourdette, D.
Venue
European Journal of Neuroscience
Publisher
Wiley
Published
2012-02
Volume
35
Issue
4
Pages
562-571
ISSN
  • 0953-816X (ISSN-L)
  • 1460-9568
OpenAlex
W1549698428
Cited by
28
References
8
FWCI
2.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetic inactivation of the p66 isoform of ShcA is neuroprotective in a murine model of multiple sclerosis. https://app.cochat.ai/papers/10.1111/j.1460-9568.2011.07972.x
The paper
Su, K. G., Savino, C., Marracci, G., Chaudhary, P., Yu, X., Morris, B., Galipeau, D., Giorgio, M., Forte, M., & Bourdette, D. (2012). Genetic inactivation of the p66 isoform of ShcA is neuroprotective in a murine model of multiple sclerosis. European Journal of Neuroscience. https://doi.org/10.1111/j.1460-9568.2011.07972.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.